CGH
TGTX icon

Crossmark Global Holdings’s TG Therapeutics TGTX Stock Holding History

Crossmark Global Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$458K Buy
8,342
+10
+0.1% +$409 0.01% 905
2026
Q1 		$277K Hold
8,332
– – ﹤0.01% 1058
2025
Q4 		$248K Buy
8,332
+662
+9% +$21.6K ﹤0.01% 1100
2025
Q3 		$277K Sell
7,670
-36
-0.5% -$1.19K ﹤0.01% 1125
2025
Q2 		$277K Buy
7,706
+1,978
+35% +$73.6K ﹤0.01% 1136
2025
Q1 		$226K Buy
+5,728
New +$193K ﹤0.01% 1212

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Crossmark Global Holdings's TGTX Position: Q2 2026 in Review

Crossmark Global Holdings increased its TG Therapeutics (TGTX) stake by 0.12% in Q2 2026, buying an estimated $409 and bringing the position to 8,342 shares worth $458K. The position accounts for 0.01% of the portfolio, ranked #905.

Crossmark Global Holdings first reported a position in TGTX in Q1 2025 and has held it in 6 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Crossmark Global Holdings held 8,342 shares of TG Therapeutics worth $458K as of Q2 2026.
  • Crossmark Global Holdings bought 10 TG Therapeutics shares in Q2 2026, an estimated $409.
  • TG Therapeutics made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #905 holding.
  • Crossmark Global Holdings first reported a position in TG Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.